BTIG analyst Robert Hazlett maintained a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Monday, setting a price target of $62, which is approximately 42.99% above the present share price of $43.36.
Hazlett expects Axsome Therapeutics Inc to post earnings per share (EPS) of -$0.86 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Axsome Therapeutics, with an average price target of $77.
The analysts price targets range from a high of $180 to a low of $25.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$30.85 million. The company's market cap is $1.63 billion.
According to TipRanks.com, BTIG analyst Robert Hazlett is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.9% and a 40.44% success rate.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.